Capricor Therapeutics Inc. (NASDAQ: CAPR) is 27.99% higher on its value in year-to-date trading and has touched a low of $0.88 and a high of $12.32 in the current 52-week trading range. The CAPR stock was last observed hovering at around $4.39 in the last trading session, with the day’s gains setting it 0.6% off its average median price target of $12.00 for the next 12 months. It is also 58.42% off the consensus price target high of $12.00 offered by 1 analysts, but current levels are 58.42% higher than the price target low of $12.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $4.99, the stock is 24.96% and 20.63% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 7.55 million and changing 13.60% at the moment leaves the stock 4.70% off its SMA200. CAPR registered 162.87% gain for a year compared to 6-month gain of 7.60%. The firm has a 50-day simple moving average (SMA 50) of $4.0803 and a 200-day simple moving average (SMA200) of $5.0252.
The stock witnessed a 5.78% loss in the last 1 month and extending the period to 3 months gives it a -10.95%, and is 17.38% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.31% over the week and 7.16% over the month.
Capricor Therapeutics Inc. (CAPR) has around 16 employees, a market worth around $82.14M and $0.50M in sales. Distance from 52-week low is 466.70% and -59.52% from its 52-week high. The company has generated returns on investments over the last 12 months (-75.80%).
Capricor Therapeutics Inc. (CAPR) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Capricor Therapeutics Inc. (CAPR) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Capricor Therapeutics Inc. is expected to release its quarterly report on 05/17/2021 and quarterly earnings per share for the current quarter are estimated at $0 with sales reaching $210k over the same period.The EPS is expected to grow by 60.10% this year, but quarterly earnings will post -75.10% year-over-year. Quarterly sales are estimated to grow 47.90% in year-over-year returns.
Capricor Therapeutics Inc. (CAPR) Top Institutional Holders
29 institutions hold shares in Capricor Therapeutics Inc. (CAPR), with 516.71k shares held by insiders accounting for 2.53% while institutional investors hold 6.36% of the company’s shares. The shares outstanding are 20.45M, and float is at 19.93M with Short Float at 3.84%. Institutions hold 6.20% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 0.34 million shares valued at $1.79 million. The investor’s holdings represent 1.67% of the CAPR Shares outstanding. As of Sep 29, 2020, the second largest holder is Susquehanna International Group, LLP with 0.28 million shares valued at $1.49 million to account for 1.39% of the shares outstanding. The other top investors are Northern Trust Corporation which holds 0.15 million shares representing 0.74% and valued at over $0.79 million, while Vanguard Group, Inc. (The) holds 0.59% of the shares totaling 0.12 million with a market value of $0.63 million.
Capricor Therapeutics Inc. (CAPR) Insider Activity
A total of 3 insider transactions have happened at Capricor Therapeutics Inc. (CAPR) in the last six months, with sales accounting for 1 and purchases happening 2 times.